IZABRIGHT-Bladder01: what clinicians are saying
izalontamab brengitecan in metastatic urothelial cancer with progression after immunotherapy · NCT07106762 ↗ · Phase 2/Phase 3 · Bristol-Myers Squibb
A physician supports the rationale for IZABRIGHT-Bladder01 amid another speaker’s description of unresolved treatment choices after EV/P. Direct trial commentary is limited; the broader sequencing context includes differing estimates of platinum activity, without enough study detail to reconcile them. These comments cannot establish the trial’s comparative benefit or safety.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 16 verified statements
This edition $750, with MCP access for your AI agent. Get this report
5 findings, and what sits behind each
01. Iza-bren versus platinum: why a clinician supports the comparison
1 of the report's 4 cited clinicians · 3 statements from 2 speakers in 1 source · 2 passages
Limitations recorded: 3.
Draws on: The comparison, Population and setting, Design and conduct.
02. Platinum after EV plus pembrolizumab: what speakers say
No named clinician · accounts and unnamed speakers · 4 statements in 2 sources · 2 passages
Limitations recorded: 4.
Draws on: The comparison, Population and setting.
Beyond the trial population
03. FGFR3/HER2: what speakers say
1 of the report's 4 cited clinicians · 2 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 2.
04. NECTIN4 after EV resistance: what a clinician asks about its validity
1 of the report's 4 cited clinicians · 4 statements from 1 speaker in 1 source · 1 passage
Limitations recorded: 2.
05. EV plus pembrolizumab resistance: why a clinician stresses trials and research access
1 of the report's 4 cited clinicians · 3 statements from 1 speaker in 3 sources · 3 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 5
1 of the report's 4 cited clinicians
Iza-bren versus platinum: why a clinician supports the comparison
3 statements from 2 speakers in 1 source
1 of the 2 named speakers in this finding holds this view, a confirmed clinician
- 3
- statements
- 2
- passages
- 1
- source
- 2
- speakers
What the statements areViews 2Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 3Giving context 0Recorded with the findingLimitations: 3
1 post or article
Draws on: The comparison, Population and setting, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
3 of the 5 findings and 9 of the 16 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (7)
ADC, antibody–drug conjugate; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival.
The full IZABRIGHT-Bladder01 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need IZABRIGHT-Bladder01’s randomized comparison to establish about the activity of izalontamab brengitecan versus platinum before choosing second-line treatment after enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer?
From findings F1 (3 statements from 2 speakers in 1 source) and F2 (4 statements in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 12commentary sources screened
- 8sources cited by verified statements
- 5named in screened sources
- 5speakers cited in the report
- 5cited speakers with a verified identity
4 cited clinicians, speakers with a confirmed clinical role, of them 4 physicians. By role and specialty:
- 3 physician, specialty not confirmed
- 1 physician, Medical oncology
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 16verified statements, each linked to its source
- 9of them from speakers with a confirmed clinical role
- 5findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 16 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 8 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
7 discussed · 5 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507no commentary found | 0 | 0 |
| Primary endpoint: Phase 3: Progression-Free Survival (PFS)no commentary found | 0 | 0 |
| Primary endpoint: Phase 3: Overall Survival (OS)no commentary found | 0 | 0 |
| Secondary endpointsno commentary found | 0 | 0 |
| Population and setting | 5 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 5 | 3 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 1 | 1 |
| External post-EV/P platinum estimates and fitness-dependent trial preference | 4 | 2 |
| Biomarker-directed alternatives and upfront testing | 2 | 2 |
| ADC switching, resistance biology and NECTIN4 uncertainty | 4 | 1 |
| Post-EV/P research priorities and referral access | 3 | 3 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
16 verified statements from 8 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 16 statements · 100% | ||||
| X threads | 16 | 8 | 12 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 6 / quarter
- Screened window
- Oct 26, 2025 → Nov 17, 2026
- Cited window
- Oct 26, 2025 → Nov 17, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
- Registry
- NCT07106762
- Study IDs
- CA244-0012 · EU CTR (2025-522400-24) · WHO (U1111-1322-9071)
- Sponsor
- Bristol-Myers Squibb
- Design
- Phase 2/Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 470 estimated
- Registered
- 2025-08-06
- Start
- 2025-09-30 actual
- Primary completion
- 2029-01-26 estimated
- Primary endpoints
- Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
- Phase 3: Progression-Free Survival (PFS)
- Phase 3: Overall Survival (OS)
- Interventions
- 4 registered
More on: Urothelial carcinoma, izalontamab brengitecan
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on emerging treatment alternatives and targets for metastatic urothelial cancer after EVP; a question about additional treatment options after immunotherapy-based treatment in metastatic urothelial cancer.
- 26 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- The sources reviewed for this edition span October 2025–November 2026 and are limited to selected X discussions and summaries; their frequency does not measure how widely clinicians hold a view.
Show all 11 known gaps +Fewer −
- Discussion using neither the trial identifier nor recognizable study or drug names, or using different acronyms, may be missing.
- No protocol or publication specific to NCT07106762 was identified in the reviewed material. Drug-label coverage was incomplete, and no exact Iza-bren label was identified; these discussions cannot establish a complete benefit–risk profile.
- The platinum estimates lack sufficient study and patient detail for direct comparison. Neither describes IZABRIGHT-Bladder01 arm outcomes.
- Two speakers relay attributed views; they are not additional clinician speakers. Reposts and quotations alone do not establish endorsement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No reviewed statement appraises the trial’s dose selection, its PFS or OS endpoint performance, or comparative safety. Silence on these subjects is not reassurance.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. IZABRIGHT-Bladder01 (NCT07106762): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/izabright-bladder01-nct07106762
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "IZABRIGHT-Bladder01" (NCT07106762), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "izabright-bladder01-nct07106762". If you cannot make requests, read https://www.erudio.com/reports/izabright-bladder01-nct07106762.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07106762", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07106762 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/izabright-bladder01-nct07106762.json
curl https://www.erudio.com/reports/izabright-bladder01-nct07106762.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "izabright-bladder01-nct07106762" })release ef7f618cb97b794dcc2d7b323df6224f1972f9d6e0cc15c8ab9ba44be7421747
Questions
How much does the IZABRIGHT-Bladder01 report cost?
One edition costs $750 (Focused · 16 verified statements · 9 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the IZABRIGHT-Bladder01 report cover?
16 statements from 8 sources (8 posts), 9 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the IZABRIGHT-Bladder01 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "izabright-bladder01-nct07106762" }) previews it and create_order({ "report": "izabright-bladder01-nct07106762", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the IZABRIGHT-Bladder01 report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.